Lyrica (Viatris Inc.)
(https://lyrica.com) 📸 Data Snapshot: May 31, 2026Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Authority is primarily derived from the Viatris Inc. corporate identity, but there is a lack of personal expert footprints. No specific clinical leads, researchers, or medical directors are identified via Person schema or sameAs links, leaving the ‘authority’ as a faceless corporate entity. The technical credibility is hampered by the repetitive [H2] YOU ARE LEAVING LYRICA.COM markers that appear in the raw text as primary content blocks, indicating a site structure that is poorly optimized for human readability compared to its regulatory requirements.
The site makes bold management claims such as ‘FDA approved for the management of fibromyalgia pain’ but provides zero supporting data from the actual clinical trials on the landing page itself. The disconnect lies between the primary signal of ‘relief’ and the total absence of ‘results’—no numbers, no charts, and no metrics are visible in the provided data. This is a classic pharma marketing pattern where the legal clearance is used as a proxy for demonstrated performance.
Identity & Authority is read from the structured data first: whether the site declares who it is in machine-readable schema, with verifiable identity links. Below is the schema captured per page, then the external proof links that support (or fail to support) that identity.
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps
Homepage schema
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"@id": "https://www.lyrica.com",
"url": "https://www.lyrica.com",
"inLanguage": "en-US",
"name": "LYRICA may help you on your path to symptom relief",
"description": "Learn about LYRICA and its FDA-approved uses, including fibromyalgia, diabetic nerve pain, spinal cord injury nerve pain, pain after shingles, and partial-onset seizures.",
"about": [
{
"@type": "MedicalCondition",
"name": "Fibromyalgia"
},
{
"@type": "MedicalCondition",
"name": "Diabetic nerve pain"
},
{
"@type": "MedicalCondition",
"name": "Spinal cord injury nerve pain"
},
{
"@type": "MedicalCondition",
"name": "Pain after shingles"
},
{
"@type": "MedicalCondition",
"name": "Partial-onset seizures"
}
],
"publisher": {
"@type": "Organization",
"name": "Viatris",
"url": "https://www.viatris.com",
"logo": {
"@type": "ImageObject",
"url": "https://www.viatris.com/-/media/project/common/viatris/viatris-logo_withouttm.svg"
}
},
"isPartOf": {
"@type": "WebSite",
"@id": "https://www.lyrica.com"
}
},
{
"@type": "Organization",
"name": "Viatris",
"url": "https://www.viatris.com",
"logo": {
"@type": "ImageObject",
"url": "https://www.viatris.com/-/media/project/common/viatris/viatris-logo_withouttm.svg"
}
},
{
"@type": "SiteNavigationElement",
"name": "Top navigation",
"inLanguage": "en-US",
"hasPart": [
{
"@type": "SiteNavigationElement",
"name": "Important Safety Information",
"url": "https://www.lyrica.com"
},
{
"@type": "SiteNavigationElement",
"name": "Full Prescribing Information",
"url": "https://www.lyrica.com"
},
{
"@type": "SiteNavigationElement",
"name": "Medication Guide",
"url": "https://www.lyrica.com"
}
]
},
{
"@type": "ItemList",
"name": "FDA-approved conditions treated with LYRICA",
"itemListOrder": "Unordered",
"numberOfItems": 5,
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Fibromyalgia"
},
{
"@type": "ListItem",
"position": 2,
"name": "Diabetic nerve pain"
},
{
"@type": "ListItem",
"position": 3,
"name": "Spinal cord injury nerve pain"
},
{
"@type": "ListItem",
"position": 4,
"name": "Pain after shingles"
},
{
"@type": "ListItem",
"position": 5,
"name": "Partial-onset seizures"
}
]
}
]
}
🛡️ Trust Signals — external proof links that back the declared identity
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 1 | 1 |
| /sign-up/ | 1 | 1 |
| /savings-card/ | 1 | 1 |
| /fm/ | 1 | 1 |
This page presents a snapshot of public data from Lyrica (Viatris Inc.), captured on May 31, 2026, to show how machine logic reads Identity & Authority signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to Lyrica (Viatris Inc.): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://lyrica.com to view the most current version of its content and see directly what this company is about and what it offers.